Payment overview · 2025
General Payments
$275,693.55
262 reported records · 12 companies
Healthcare provider profile · identity verified
Aaron L Ellenbogen, D.O.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · FARMINGTON HILLS, MI · NPI 1962472241
Verified facts
What the public records show
CMS Open Payments records show Aaron L Ellenbogen, D.O. received $275,693.55 in general payments during 2025 across 262 reported records.
ABBVIE INC. accounted for 38.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Apokyn, Austedo Xr, Crexont, Gocovri.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREXONT as an associated drug or biological on 11358 records involving 3581 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Crexont by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ongentys by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Rytary by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Apokyn as an associated drug or biological on 1207 records involving 338 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Apokyn by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Gocovri by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $106,007.55 | 38.5% | 105 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $102,677.30 | 37.2% | 98 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $38,228.31 | 13.9% | 26 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16,631.77 | 6.0% | 17 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $6,228.52 | 2.3% | 5 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $4,225.00 | 1.5% | 2 | 2025 |
| F. Hoffmann-La Roche AG | Unresolved — no canonical attribution shown | $1,280.08 | 0.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $212.50 | 0.1% | 3 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $83.37 | 0.0% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.41 | 0.0% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $21.31 | 0.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.43 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $109,300.00 | 30 |
| Honoraria | $83,961.50 | 23 |
| Consulting Fee | $48,453.75 | 16 |
| Travel and Lodging | $26,820.95 | 114 |
| Food and Beverage | $5,999.35 | 78 |
| Education | $1,158.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $78,356.80 | 77 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $38,228.31 | 26 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16,631.77 | 17 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14,378.18 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $12,990.72 | 11 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $9,514.03 | 9 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $6,993.83 | 11 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $6,228.52 | 5 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $83.37 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $5.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Apokyn apokyn |
2025 | Apokyn | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREXONT crexont |
2025 | Crexont | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gocovri gocovri |
2025 | Gocovri | 2024 | 106 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | CREXONT open payments reported associated product |
CMS Open Payments — General Payments 11358 supporting records · 3581 recipient NPIs · example record 1220525531 |
Crexont · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
152 | 36 |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Apokyn open payments reported associated product |
CMS Open Payments — General Payments 1207 supporting records · 338 recipient NPIs · example record 1241843684 |
Apokyn · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
106 | 13 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 1032 | 341 |
| Clonazepam | Clonazepam | 195 | 44 |
| Amantadine | Amantadine Hcl | 156 | 45 |
| Rytary | Carbidopa/Levodopa | 152 | 36 |
| Gabapentin | Gabapentin | 139 | 51 |
| Donepezil Hcl | Donepezil Hcl | 129 | 45 |
| Memantine Hcl | Memantine Hcl | 125 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 114 | 33 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 109 | 38 |
| Gocovri | Amantadine Hcl | 106 | 13 |
| Nuplazid | Pimavanserin Tartrate | 96 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 96 | 29 |
| Propranolol Hcl Er | Propranolol Hcl | 85 | 26 |
| Baclofen | Baclofen | 81 | 29 |
| Zonisamide | Zonisamide | 80 | 17 |
| Topiramate | Topiramate | 79 | 25 |
| Pregabalin | Pregabalin | 75 | 18 |
| Sertraline Hcl | Sertraline Hcl | 75 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 26 |
| Primidone | Primidone | 73 | 34 |
| Levetiracetam | Levetiracetam | 72 | 18 |
| Rasagiline Mesylate | Rasagiline Mesylate | 61 | 25 |
| Methadone Hcl | Methadone Hcl | 56 | suppressed |
| Austedo Xr | Deutetrabenazine | 52 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 52 | suppressed |
| Entacapone | Entacapone | 50 | 16 |
| Ropinirole Er | Ropinirole Hcl | 45 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 14 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | 13 |
| Lacosamide | Lacosamide | 37 | suppressed |
| Rivastigmine | Rivastigmine | 36 | 14 |
| Diazepam | Diazepam | 35 | 11 |
| Inbrija | Levodopa | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Neupro | Rotigotine | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 28 | suppressed |
| Ongentys | Opicapone | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 26 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Austedo | Deutetrabenazine | 23 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Ingrezza | Valbenazine Tosylate | 21 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 21 | suppressed |
| Apokyn | Apomorphine Hcl | 20 | suppressed |
| Nourianz | Istradefylline | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Briviact | Brivaracetam | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Crexont | Carbidopa/Levodopa | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Teriflunomide | Teriflunomide | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Droxidopa | Droxidopa | 11 | suppressed |
| Horizant | Gabapentin Enacarbil | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $275,693.55 · 262 records | ABBVIE INC. | AUSTEDO XR, Apokyn, BOTOX, CREXONT, DAXXIFY, Dysport, Gocovri, KESIMPTA, QULIPTA, UBRELVY, VYALEV, Vest Therapy Und | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Apokyn play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amneal Pharmaceuticals LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error